Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–7 of 7 results
Advanced filters: Author: Patrik Frei Clear advanced filters

  • As well as overcoming legal, cultural and linguistic barriers, European biotech companies must focus on building investor visibility, pharma collaborations and consolidation to boost their chances of successful exits.

    • Peter Buckel
    • Ulrich Dauer
    • Jean-Yves Nothias
    Comments & Opinion
    Bioentrepreneur
    P: 1-5

  • A genome-wide association study including over 76,000 individuals with schizophrenia and over 243,000 control individuals identifies common variant associations at 287 genomic loci, and further fine-mapping analyses highlight the importance of genes involved in synaptic processes.

    • Vassily Trubetskoy
    • Antonio F. Pardiñas
    • Jim van Os
    Research
    Nature
    Volume: 604, P: 502-508

  • A species-level phylogenetic analysis of the high-elevation flora of the European Alps reveals that the flora is young and colonist rich. Its assembly was primarily driven by the Pleistocene climatic cycles, rather than ancient orogenic events.

    • Lara M. Wootton
    • Florian C. Boucher
    • Sébastien Lavergne
    Research
    Nature Plants
    Volume: 11, P: 1142-1153

  • Could a mathematical model predict the total value of licensing deals?

    • Elias Neuendorf
    • Kara E. O’Connell
    • Kumlesh K. Dev
    News
    Biopharma Dealmakers

  • The basics of determining valuation will help you to understand what criteria matter most for investors.

    • Patrik Frei
    • Benoît Leleux
    Comments & Opinion
    Bioentrepreneur
    P: 1-3

  • The pharmaceutical and biotechnology industries see over 3,000 deals signed every year, many of which involve the complex and often unfamiliar process of valuing potential products that are not yet on the market. In this feature, valuation specialists Venture Valuation explain how the value of a product is calculated and how this relates to the overall deal value.

    • Aitana Peire
    • Patrik Frei
    News
    Biopharma Dealmakers